NCT05078593View on ClinicalTrials.gov

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 11, 2021

Primary Completion Date

August 18, 2023

Study Completion Date

August 18, 2023

Conditions
Solid Tumor, AdultLymphoma
Interventions
DRUG

HLX26

Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Shanghai Henlius Biotech

INDUSTRY

NCT05078593 - A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma | Biotech Hunter | Biotech Hunter